Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Operating Expenses (2019 - 2025)

Harmony Biosciences Holdings' Operating Expenses history spans 7 years, with the latest figure at $136.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 49.98% year-over-year to $136.7 million; the TTM value through Dec 2025 reached $461.6 million, up 25.76%, while the annual FY2025 figure was $461.6 million, 25.76% up from the prior year.
  • Operating Expenses for Q4 2025 was $136.7 million at Harmony Biosciences Holdings, up from $114.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $136.7 million in Q4 2025 and bottomed at $34.7 million in Q1 2021.
  • The 5-year median for Operating Expenses is $69.3 million (2023), against an average of $74.7 million.
  • The largest annual shift saw Operating Expenses fell 22.93% in 2023 before it surged 91.5% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $44.8 million in 2021, then increased by 20.21% to $53.8 million in 2022, then surged by 58.08% to $85.1 million in 2023, then increased by 7.13% to $91.1 million in 2024, then skyrocketed by 49.98% to $136.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Operating Expenses are $136.7 million (Q4 2025), $114.3 million (Q3 2025), and $114.2 million (Q2 2025).